NIH VideoCast - Current and Future Research Needs in the Era of Highly Effective Modulator Therapies for Cystic Fibrosis - Day 1

Skip Navigation

Current and Future Research Needs in the Era of Highly Effective Modulator Therapies for Cystic Fibrosis - Day 1

Loading... Loading video...

487 Views

Air date:	Thursday, June 2, 2022, 9:00:00 AM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 487 (406 Live, 81 On-demand)
Category:	Conferences
Runtime:	06:13:47
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Cystic fibrosis (CF) is a rare inherited disease caused by mutations in a gene called the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Mutations in CFTR cause significant morbidity and mortality for patients with CF, primarily affecting the lungs and digestive systems. With no cure for CF, advances in treatment using highly effective modulator therapies (HEMT) are helping patients live longer lives with improvements in clinical outcomes.On Thursday, June 2, and Friday, June 3, 2022, the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) in planning collaboration with the Cystic Fibrosis Foundation will host a virtual workshop with the objective to bring together experts in Cystic Fibrosis (CF) clinical-translational research to address critical questions and inform the field of the future research needs in the era of highly effective modulator therapies (HEMT) for the treatment of CF. The workshop will highlight challenges and opportunities for research in the context of rapidly shifting treatment options. The workshop is free, open to the public, and will be recorded. For more information go to https://www.nhlbi.nih.gov/events/2022/current-and-future-research-needs-era-highly-effective-modulator-therapies-cystic

NLM Title:	Current and future research needs in the era of highly effective modulator therapies for cystic fibrosis / NIH, NHLBI, NIAAD, NIDDK, and Cystic Fibrosis Foundation.
Author:	Current and Future Research Needs in the Era of Highly Effective Modulator Therapies for Cystic Fibrosis (Workshop) National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): Cystic fibrosis (CF) is a rare inherited disease caused by mutations in a gene called the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Mutations in CFTR cause significant morbidity and mortality for patients with CF, primarily affecting the lungs and digestive systems. With no cure for CF, advances in treatment using highly effective modulator therapies (HEMT) are helping patients live longer lives with improvements in clinical outcomes. On Thursday, June 2, and Friday, June 3, 2022, the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) in planning collaboration with the Cystic Fibrosis Foundation will host a virtual workshop with the objective to bring together experts in Cystic Fibrosis (CF) clinical-translational research to address critical questions and inform the field of the future research needs in the era of highly effective modulator therapies (HEMT) for the treatment of CF. The workshop will highlight challenges and opportunities for research in the context of rapidly shifting treatment options.
Subjects:	Cystic Fibrosis--therapy
Publication Types:	Congress Webcast

NLM Classification:	WI 820
NLM ID:	9918434186406676
CIT Live ID:	45631
Permanent link:	https://videocast.nih.gov/watch=45631

Related Videos...